


IFW



DOCKET No.: SSBC-0001 (121300.00003)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hu, Fang, et al.,

Serial No.: 10/766,307

Filed: January 28, 2004

Group: NA

For: THERAPY FOR PRIMARY AND METASTATIC CANCER

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

<p>CERTIFICATE OF MAILING UNDER 37 CFR 1.8: I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on October 26, 2004.</p> <p><i>M. Alford</i></p> <p>Signature</p> <p><i>M. ALFORD</i></p> <p>Typed or Printed name of person signing Certificate</p>
--

FIRST SUPPLEMENTAL TRANSMITTAL OF INFORMATION DISCLOSURE  
STATEMENT

Applicant certifies under 37 C.F.R. § 1.97(d)(2)(1) that the references contained in the information disclosure statement filed herewith were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.

Respectfully submitted,  
JACKSON WALKER L.L.P.

*T. Ling Chwang*

T. Ling Chwang  
Registration No. 33,590

October 26, 2004  
Date:

JACKSON WALKER L.L.P.  
2435 North Central Expressway, Suite 600  
Richardson, Texas 75080  
Tel: (972) 744-2919  
Fax: (972) 744-2909





Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2 Sheets

**Complete if Known**

Application Number	10/766,307
Filing Date	01/28/04
First Named Inventor	Hu, et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	SSBC-00001 (121300.0003)

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	2.	HAVIV YS, Blackwell JL, Li H, Wang M, Lei X, Curiel DT. Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus. Cancer Res. 2001 Dec 1;61(23):8361-5.	
	3.	RIES S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer. 2002 Jan 7;86(1):5-11.	
	4.	KRUYT FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther. 2002 Mar 1;13(4):485-95.	
	5.	FALK MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia. 2001 Jan-Feb;17(1):1-18.	
	6.	International Search Report, International Application No. PCT/US 04/002330 September 8, 2004	

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.